NCT03212261View on ClinicalTrials.gov

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

NACompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

September 24, 2018

Conditions
Lymphoma
Interventions
BEHAVIORAL

3RP-Lymphoma

An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

lead

Massachusetts General Hospital

OTHER

NCT03212261 - Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma | Biotech Hunter | Biotech Hunter